fda glp-1 compounding enforcement news Fmr. Commissioner weighs in on Medicare's involvement in prices Federal watchdog looks at compounded

Description

GLP-1 agonists have demonstrated safety and efficacy in clinical trials for weight loss, but individual safety depends on medical history, dosing protocol, and ongoing provider oversight

Digital weight loss company Noom has entered the evolving GLP-1 medication landscape with the launch of its Noom Microdose GLP-1Rx Program, offering members personalized microdoses of GLP-1 medications combined with behavioral coaching and clinical support

Millions of Medicare beneficiaries could save tens of thousands a year as the Feds make a multibillion dollar bet.

Beyond their roles in diabetes treatment, AGIs have shown potential in extending lifespan and effectively treating aging-related diseases by modulating oxidative stress, gut microbiota, inflammatory responses, and nutrient-sensing pathways